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There is some controversy regarding the hypothesis that psycho-
social factors impact upon relapse and survival in cancer patients.
Several prospective and intervention studies have found an
association between psychosocial factors and outcome (Stavraky
et al, 1988; Spiegel et al, 1989; Greer et al, 1990; Fawzy et al,
1993; Molassiotis et al, 1997; Butow et al, 1999). Other studies
have failed to find any association (Jamison et al, 1987; Tross et al,
1996).
The reasons for these inconsistencies are complex, ranging from
methodological problems in the research itself, to a lack of under-
standing about the psychological and/or biological processes that
may be involved. For example, inadequate sample size and the
omission of important prognostic indicators have been commonly
cited as problematic (Mulder et al, 1992). Research in this area is
also confused by the diverse array of study designs with differ-
ences in the psychosocial constructs measured, cancer types
sampled, prognostic covariates included, type of analysis and
timing of assessments. For this reason it is important to systemati-
cally explore differences between cancer stages and types using
the same variables and study design.
The current study is part of a larger project examining the asso-
ciation between psychosocial factors and outcome in early and
advanced stage disease for melanoma and breast cancer patients.
We are now seeking to highlight the differences between
metastatic and early stage melanoma through a comparison of the
results. Psychosocial variables were selected to encompass a
comprehensive model of response to illness. Previously Butow
et al (1999) found that a range of quality of life variables,
psychosocial variables, marital status and perceived aim of
treatment predicted survival duration in a group of metastatic
melanoma patients. Specifically, results showed that patients who
were (i) more positive about their expected survival, (ii) mini-
mized the impact of their cancer on their daily lives or (iii) who
felt more angry, were more likely to have longer survival.
Few studies have specifically examined relationships between
psychosocial factors and outcome in patients with early stage
melanoma. Previous studies suggest that coping style may be
important (Rogentine et al, 1979; Fawzy et al, 1993). Fawzy et al
(1993) in a randomized controlled trial found that baseline coping
(active-behavioural) and changes in coping were predictive of
outcome. Rogentine et al (1979) found that non-relapsers reported
a significantly higher effort to cope with their illness. Coping style
has also been found to be associated with outcome in early stage
breast cancer (Greer et al, 1990; Watson et al, 1999), although this
association has not been found in European samples (Buddeberg
et al, 1996; Giraldi et al, 1997).
The aim of this study was to explore the relationships between
these psychosocial variables and relapse and survival in a group of
patients with locoregional melanoma using a methodologically
sound design and large sample size.
PATIENTS AND METHODS
The study population consisted of patients with locoregional
melanoma first seen at the Sydney Melanoma Unit between 1991
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doi: 10.1054/ bjoc.2000.1471, available online at http://www.idealibrary.com on  http://www.bjcancer.comand 1996. Exclusion criteria included tumour thickness of less
than 0.7 mm, time since diagnosis greater than one year,
psychiatric illness and inability to speak English fluently.
Participating patients were asked to complete a series of
questionnaires that were repeated every 3 months, where possible,
for up to 2 years. However, for the purposes of this paper, data
were taken from the first questionnaire only. A subsequent paper
will explore the impact of longitudinal data on survival. Follow-up
was terminated in October 1997 and data censored at that time.
Disease and demographic data were obtained from medical
records. At the close of the study, disease status and outcome were
determined through a search of computerized and paper-based
medical records and, where necessary, by contact with the patient’s
general practitioner or the NSW cancer registry.
Psychosocial assessment
Measures were chosen to systematically obtain data on the range
of psychosocial factors thought to be associated with human
responses to illness. The measures have proven psychometric
status and applicability to cancer populations.
Cognitive appraisal of threat: independence, family and
disease
Cognitive appraisal is the process by which a person evaluates
the implicit threat in a stressful encounter. We used the 13-item
cognitive appraisal subscale of the Stress Questionnaire (Folkman,
1986). Each item has a 5-point Likert scale from ‘worries me a
lot’ to ‘does not worry me at all’. Factor analysis in a sample of
125 metastatic melanoma patients yielded 3 factors concerning
independence, family and disease (Butow et al, 1999). Cronbach
alphas for these 3 factors in this sample were 0.85, 0.79 and 0.69,
respectively. Examples of these factors are ‘that I will not be able
to work’ (Independence), ‘that my family will be upset’ (Family),
‘that I will have to cope with a lot of pain’ (Disease). Items were
summed to a factor score and were linearly transformed to a scale
of 0 to 100, with high scores indicating more concern/distress.
Coping: active, distraction and avoidant
Coping is the process of managing demands (external or internal)
that are appraised as taxing or exceeding the resources of a person.
We used a self-report adaptation of the Weisman and Wordon
General Coping Strategies Scale, the COPE, which measures the
frequency of use of 15 problem-solving and emotion-focused
coping strategies (Weisman and Worden, 1976–77). The COPE
has been used successfully with cancer patients, and has been
shown to be sensitive to age, diagnosis and staging of the illness.
Patients indicated on a 5-point Likert scale the frequency with
which they used each coping style (never to always). Factor
analysis of the COPE in a sample of 125 metastatic melanoma
patients yielded 3 factors: active, distraction and avoidant coping
(Butow et al, 1999). Cronbach alphas for the 3 factors in this
sample were 0.65, 0.51 and 0.24, respectively. Examples of
these factors are ‘seeking more information about the situation’
(Active), ‘trying to forget, putting it out of my mind, distracting
myself’ (Distraction) and ‘drinking, eating or taking drugs to feel
less tense’ (Avoidant). Items were summed and linearly trans-
formed to a scale of 0 to 100, with a high score indicating frequent
use of that coping style.
Psychological adjustment: isolation, minimization and anger
This concept is defined as the functional outcome of coping,
including maintenance of emotional equilibrium, acceptance of the
illness and maintenance of positive self-esteem. Psychological
adjustment was measured using the 53-item Psychological
Adjustment to Cancer scale (PAC), developed by Dunn et al
(1997). The sensitivity of the PAC has been demonstrated in a
randomized controlled trial assessing the impact of the use of the
word ‘cancer’ and euphemisms for it (Dunn et al, 1993). Patients
indicated on a 5-point Likert scale the degree to which they agreed
or disagreed with each statement. A factor analysis in a sample
of 125 metastatic melanoma patients resulted in a shorter 24-item,
3-factor scale, measuring stigma/isolation, minimization and anger
(Butow et al, 1999). Cronbach alphas for the 3 factors in this
sample were 0.81, 0.57 and 0.65, respectively. Raw scores were
linearly transformed to a scale of 0 to 100. High scores indicate
greater levels of isolation, minimization and anger. Stigma/isola-
tion items included ‘I try not to let people know about my cancer’
and ‘since getting cancer my body has felt unclean’. Minimization
items included ‘having cancer is not making any difference to my
life at all’ and ‘the thought of having treatment does not worry
me’. Anger items included ‘cancer is the worst thing that has
ever happened to me’ and ‘I am constantly asking myself the
question – why me?’
Perceived aim of treatment
Patients’ perceived aim of treatment was measured at the initial
assessment. Patients chose between 4 response options: complete
cure, increased chances of long-term survival, increased chances
of short-term survival or reduction of symptoms. In these analyses,
patients who selected complete cure as their aim of treatment were
compared with all other responses.
Quality of life (QOL) indicators
Indicators of QOL were assessed using 3 single-item LASA scales
measuring physical well-being, mood and perceived effort to cope
(Priestman and Baum, 1976; Hurny et al, 1993). The scales were
scored from 1 to 100 using a 100 mm line. Each scale is anchored
at either end by phrases representing extremes of experience. Thus
physical well-being is anchored by ‘lousy’ and ‘good’; mood is
anchored by ‘miserable’ and ‘happy’ and effort to cope is
anchored by a ‘great deal of effort’ and ‘no effort at all’. On each
scale, a higher score reflects better QOL. These scales have beeen
found to have adequate reliability and validity (Butow et al, 1991;
Hurny et al, 1993; Bernhard et al, 1997).
Disease and demographic variables
The following demographic and disease prognostic factors were
recorded and included in analyses: age, gender, marital status
(whether patients were in a relationship), time since diagnoses,
tumour site and thickness, presence of ulceration, number of
mitoses, and recent treatment received (Millar et al, 1998).
Tumour sites were recorded into 4 variables. These were
(i) legs/arms, (ii) head/neck, (iii) thorax and (iv) other. In this
analysis, the absence of melanoma at a site is the reference for
comparison with the other groups. Patients were also divided into
those who had (i) no previous locoregional metastases (referent
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tumours and delayed or synchronous nodes. The referent groups
for gender, ulceration and treatment were female, no ulceration
and no treatment.
Statistical analysis
Relapse-free survival was measured from the time patients
completed their first questionnaire (date of study entry) to their
first relapse or to the date of censoring. Likewise survival was
calculated as the time between the date of study entry and either
death from melanoma or the censor date.
Data were analysed in a two-step process. First, the best subset
of explanatory variables was selected according to the method of
Lawless and Singhal (Lawless and Singhal, 1978). The best subset
method is preferable to the stepwise method when there are many
covariates, particularly when the covariates are inter-related
(Ciampi et al, 1988). Once the best subset of variables was identi-
fied, multivariate analysis was conducted using Cox Regression
Analysis. Variables included in the final model were tested using
the likelihood ratio test (χ 2 distribution, P < 0.05). All calculations
were performed using the SPIDA statistical package (Gebski et al,
1992).
RESULTS
426 of 682 eligible patients agreed to participate in the study.
Participants and non-participants did not differ on gender (χ 2 test,
0.12; P = 0.73), marital status (χ 2 test, 0.73; P = 0.40) locoregional
metastases (χ 2 test, 2.87; P = 0.09). or tumour thickness (t test,
1.58; P = 0.11). There was also no difference on time to relapse
(Log-rank test, 0.01; P = 0.99) or survival duration (Logrank test,
1.97; P = 0.16) when measured from the time patients were invited
to join the study. Non-participants were older (t test, 3.73;
P < 0.001) and had a greater number of mitoses (t test, –3.23;
P <0.001). Distinguishing differences between participants and
non-participants are summarized in Table 1.
Of the 505 participants, 79 were excluded from the sample as
their time since diagnosis exceeded 1 year. From the final sample
of 426, 91 (21%) patients relapsed and 60 (14%) patients died
from melanoma within the follow-up period. The majority of the
sample was Australian-born, male and married. Mean time since
diagnosis was 4.5 months with only 6% of the sample entering the
study within 2 months of diagnosis. Disease and demographic
characteristics of the sample are shown in Table 2.
Psychological data and QOL indicators
Summaries of the psychological variables and QOL indicators for
patient outcomes are presented in Table 3. This table suggests that
the largest differences were found on the scales measuring patient
concerns but overall differences between these patient groups
were not very great. On average patients who relapsed or died
reported using more active, distraction or avoidant styles of
coping.
Relapse-free survival and overall survival
Variables included in the multivariate analyses were selected using
the best-subset method (Lawless and Singhal, 1978). Variables
found to be significant in the multivariate analysis using Cox
Regression Analysis are presented in Table 4.
While controlling for important prognostic indicators, it was
found that patients who perceived their aim of treatment to be
cure, who used less avoidance as a coping strategy and who were
more concerned about their disease had longer relapse-free
survival. 87% of patients who did not relapse perceived their treat-
ment aim as complete cure, versus 71% of those who did relapse.
The relapse-free survival graph for perceived aim of treatment is
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Table 1 Comparison between non-participants (n = 256) and participants
(n = 426) on demographic and disease variables
Non-participants Participants P value
Mean (SE) Mean (SE)
Variable name
Time since diagnosis (months)a 3.9 (0.1) 3.3 (0.1) <0.01
Time to relapse (mean (years))b 1.6 (0.2) 1.7 (0.1) 0.81
Time to death (mean (years))b 2.2 (0.2) 2.92 (0.2) 0.30
Mitoses 3.7 (0.0) 4.5 (0.3) <0.01
Thickness 2.6 (0.2) 2.3 (0.1) 0.11
Age 57 (1.0) 53 (0.8) <0.01
% (respondents) % (respondents)
Ulceration 27 30 0.46
Loco-regional metastases 11 16 0.09
Gender (males) 60 61 0.73
Marital status 70 73 0.40
(in a relationship)
aTime measured between diagnosis and date of invitation. bTime measured
between date of invitation and relapse or survival.
Table 2 Demographic and disease characteristics of the final sample
(n = 426)
Mean (SD)
Age (years) 53 (16)
Time since diagnosis to study entry (months) 4.5 (2)
Tumour thickness (mm) 2.3 (1.7)
%
Demographic
Gender Male 61
Education Primary 6
Intermediate 56
HSC or equivalent 13
Technical 6
Undergraduate/postgraduate 19
Occupation Managers/administrators/professionals 42
Tradespersons 13
Sales/personnel/clerks 26
Machine operators/labourers 16
Home duties 3
Ethnicity Australian 88
Marital status Single 12
Married/de facto 73
Separated/divorced 9
Widowed 6
Disease
Ulceration None 73
Primary site Occult 4
Legs/arms 39
Head/neck 16
Thorax 40
Other 1
Loco-regional No 84
metastasis
Perceived aim Complete cure 84
of treatment Increased chances of long-term survival 12
Reduction of discomfort 1
Don’t know 3shown in Figure 1. A different picture emerged if overall survival
was taken as the outcome. Longer overall survival was associated
with a negative mood, not using avoidance as a coping strategy,
being concerned about the disease and not being concerned about
its impact on the family.
DISCUSSION
This study explored psychosocial predictors of outcome in
426 patients with early stage melanoma. While controlling for
known prognostic variables, several psychosocial variables
independently predicted time to relapse and/or survival duration.
Those patients who used less avoidant coping strategies or who
were more concerned about their disease overall, had a better
outcome both in terms of time to relapse and survival duration.
These findings are perhaps linked to preventative behaviours. By
having a concern for their disease and not avoiding it, patients may
be better able to look after themselves and engage in appropriate
self-care, for example, have regular check-ups. Unfortunately,
preventative behaviours were not monitored in the current study,
so this link cannot be definitively established. Future research
needs to identify and monitor other factors that may help establish
these relationships.
Of the psychosocial variables, perceived aim of treatment had
the greatest impact on time to relapse but was not associated with
survival duration. Long-term associations may be weakened by the
fact that some patients’ perceptions about the treatment aim may
not be stable over time, especially once the disease has spread.
Unfortunately, this variable was only measured at baseline, so that
conclusions about stability of this variable over time and situation
cannot be made. Furthermore it is difficult to ascertain the degree
to which patients’ perception of their aim of treatment reflects a
realistic understanding of their objective circumstanc
or a specific ‘optimistic/non-optimistic’ psychological response or
coping style. Further research is needed to clarify the factors influ-
encing this perception, for example the degree to which patients
base their expectations on the information provided by their
treating physician.
Nevertheless, these results for perceived aim of treatment are
consistent with those of Butow et al (1999) who found that
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Table 3 Descriptive statistics for psychological variables and QOL indicator
variables
Non-relapsers Relapsers Died
Mean (Std Err) Mean (Std Err) Mean (Std Err)
Psychological adjustment
Isolation 79 (0.7) 78 (1.5) 83 (1.7)
Minimization 61 (0.9) 62 (1.6) 59 (2.2)
Anger 38 (0.3) 40 (1.7) 35 (2.3)
Coping style
Active 45 (1.3) 49 (2.2) 51 (3.3)
Distraction 33 (1.0) 35 (1.9) 36 (1.0)
Avoidance 35 (0.7) 38 (1.4) 38 (1.9)
Concerns
Independence 17 (1.2) 17 (2.7) 16 (2.9)
Family 24 (1.3) 30 (3.5) 32 (5.0)
Disease 17 (1.0) 13 (1.7) 12 (1.7)
QOL Indicators
Physical 78 (1.4) 77 (3.7) 81 (3.8)
Mood 77 (1.3) 77 (3.5) 81 (3.0)
PACIS 79 (1.3) 90 (1.7) 85 (2.9)
Table 4 Final models for predictors of time to relapse and overall survival
Relapse Survival
P value Hazard 95% CI P value Hazard 95% CI
Disease variables
Thickness <0.001 1.33 1.19–1.49 <0.001 1.34 1.17–1.53
Ulceration 0.005 2.03 1.24–3.31
Head/neck 0.02 2.63 1.19–5.78
Thorax 0.07 2.01 0.95–4.24
Prior loco-regional <0.001 4.32 2.60–7.18 <0.001 3.54 1.83–6.83
Metastasis
Perceived 0.06 0.59 0.34–1.02
Aim of treatment
Quality of life
Mood 0.06 1.02 1.00–1.03
Coping style
Avoidant coping 0.03 1.02 1.00–1.04 0.08 1.02 1.00–1.05
Concerns
Family 0.03 1.01 1.00–1.02
Disease 0.008 0.98 0.96–0.99 0.01 0.97 0.95–0.99
– 1 0123
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Fig 1. Survival graph for time to relapse for perceived aim of treatment.perceived aim of treatment predicted survival in patients with
metastatic melanoma. Thus where the disease is stable, this
variable is associated with a significantly improved outcome in
both early and late stage melanoma, supporting the need to further
explore possible explanations for its impact.
Curiously, patient concern about family was found to have a
hazardous effect on survival duration while patient concern about
disease was found to be protective. This implies that these factors
are not surrogates for a general measure of anxiety, but identify
specific elements related to the cancer experience. Perhaps
patients who are more concerned about their family experience
signs and symptoms of worse disease. Alternatively, those
concerned about their family may be more likely to direct their
resources to their family and not to themselves. In any case, these
results suggest that addressing issues about the impact of disease
on both patients themselves and on their family could be beneficial
for their overall outcome.
The findings of this study are consistent with other research
reporting that coping style was associated with outcome in patients
with primary melanoma (Fawzy et al, 1993). However, these
results differ in terms of the specific coping styles found to be
protective. For example, Fawzy et al (1993) found that an active
coping style, and not an avoidant one, was associated with
outcome. This discrepancy may be due to subtle differences in the
items included within the measures. The low Cronbach alpha for
the measure of avoidance in this study needs to be carefully
considered. While the low alpha does not detract from the results
themselves it may suggest that the items do not exclusively
measure ‘avoidance’.
The relationship between mood and survival appears to be
complex. There is some evidence to suggest that a negative
‘depressive’ mood is associated with a shorter overall survival
(Faller et al, 1999; Watson et al, 1999). However, the general
measure of mood used in this study may not reflect a ‘depressive’
mood but rather encompass other dimensions such as anger
(Brown et al, in press). Anger has been shown to have a survival
advantage in advanced stage patients (Butow et al, 1999).
While perceived aim of treatment has been found to be consis-
tently associated with improved outcomes, other findings of this
study differed from those of Butow et al (1999), even though the
same variables were measured. For example, patients who mini-
mized the impact of their cancer were found to have increased
survival in patients with late stage but not early stage disease.
Other research has also found that different patterns emerge when
variables are measured at different times in the disease course. For
example, Dean and Surtees (1989) found that outcome was associ-
ated with the use of stoic acceptance in the pre-operative period
and denial in the postoperative period. Likewise Cassileth et al
(1988) found differences in the pattern of results for early and late
stage patients.
One explanation for these differences could be that different
factors exert their influence at different stages in the disease
course. The predictive capacity of biological variables is often
limited to particular stage of the illness. For example, tumour
thickness is a good predictor of an initial recurrence, but is not
predictive of overall survival once a recurrence has occurred
(Cohn-Cedermark et al, 1999). Dimensions of psychological expe-
rience may operate in a similar manner with certain dimensions
being more prominent at one time versus another. It is apparent
that patients’ psychological experience does vary across time
(Heim et al, 1997). There are marked differences between early
and late stage disease, for both physical experiences (e.g., surgery,
chemotherapy) and existential issues that need to be faced
(e.g., pain, death).
Overall, there is still much to learn about the potential relation-
ships between psychological well being, human behaviours and
the disease process. Research in this area needs to clarify the
psychological processes themselves as well as to understand the
biological and/or behavioural mechanisms that may link them to
outcome.
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